Guselkumab induction therapy demonstrates long-lasting efficacy in patients with mild psoriasis, results from a randomized, placebo-controlled exploratory clinical trial - 11/01/24
Doi : 10.1016/j.jaad.2023.09.071
Jannik Rousel, MSc a, b, Menthe E. Bergmans, MD a, c, Laura W.J. van der Meulen, MD a, d, Lisa Pagan, MD a, c, Digna T. de Bruin, MD a, c, Marieke L. de Kam, MSc a, Naomi B. Klarenbeek, MD, PhD a, Joke A. Bouwstra, PhD b, Marieke M.B. Seyger, MD, PhD e, Juul M.P.A. van den Reek, MD, PhD e, Tessa Niemeyer-van der Kolk, MD, PhD a, Robert Rissmann, PhD a, b, c, ⁎ 
, Martijn B.A. van Doorn, MD, PhD a, d
and the
, Martijn B.A. van Doorn, MD, PhD a, dand the
NGID consortium
a Centre for Human Drug Research, Leiden, The Netherlands
b Leiden Academic Centre for Drug Research, Leiden University, Leiden, The Netherlands
c Leiden University Medical Center, Leiden, The Netherlands
d Department of Dermatology, Erasmus University Medical Center, Rotterdam, The Netherlands
e Department of Dermatology, Radboud University Medical Center, Nijmegen, The Netherlands
∗Correspondence: Robert Rissmann, PhD, Centre for Human Drug Research, Zernikedreef 8, 2333CL, Leiden, the NetherlandsCentre for Human Drug ResearchZernikedreef 8Leiden2333CLthe Netherlands
Key words : disease modification, guselkumab, IL-23, mild psoriasis, relapse
| Rousel and Dr Bergmans contributed equally to this work. |
|
| Funding sources: CHDR funded this investigator-initiated trial. Janssen-Cilag BV provided the medication for use in the clinical study and was involved in the approval of the study protocol and publication. This study is part of the SKINERGY PP trial under NWA-ORC project NWA.1389.20.182 entitled Next Generation Immuno Dermatology (NGID). |
|
| IRB approval status: Reviewed and approved by the Medische Ethische ToetsingsCommissie Brabant (IRB approval number P1926). |
|
| Patient consent: The patients have given consent for this report to be published. |
© 2023
Publié par Elsevier Masson SAS.
Vol 90 - N° 2
P. 395-397 - février 2024 Retour au numéro
Article précédent
- Onset of psoriasis with immune checkpoint inhibitor therapy: A systematic review
- Nawar Tarafdar, Muskaan Sachdeva, Iryna Savinova, Yuliya Lytvyn, Khalad Maliyar, Jorge R. Georgakopoulos, Asfandyar Mufti, Jensen Yeung
- Assessing the ability of an artificial intelligence chatbot to translate dermatopathology reports into patient-friendly language: A cross-sectional study
- Yuying Zhang, Ryan Chen, Dan Nguyen, Stephanie Choi, Colleen Gabel, Nicholas Leonard, Kaitlyn Yim, Patrick O'Donnell, Zendee Elaba, April Deng, Nikki A. Levin
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?